Psychopharmacology in Oncology and Palliative Care: General Issues

At least 25–30 % of patients with cancer and even a higher percentage of those in an advanced phase of illness meet the criteria for a psychiatric diagnosis, including depression, anxiety, stress-related syndromes, including severe adjustment disorders, sleep disorders, and delirium. A number of studies in psychooncology have accumulated over the last 35 years on the use of psychotropic drugs as a pillar in the treatment of psychiatric disorders. Major advances in research have also shown the efficacy of psychotropic drugs as adjuvant treatment of cancer-related symptoms, such as pain, hot flashes, pruritus, nausea and vomiting, fatigue, and cognitive impairment. The knowledge about pharmacokinetics and pharmacodynamics, clinical use, safety, side effects, and efficacy of drugs in cancer care is essential. The aims of this chapter are to consider the need for an integrated psychological and psychopharmacological intervention, as the concept of psychopharmoncology specifies, favoring the vision of an integrated and multidimensional approach in oncology, and palliative care services as well as in community-based cancer centers